Learning Center

Your central location for online learning and education surrounding all aspects of tissue donation, tissue banking, research and transplantation.

2024 Webinar Series: From Concept to SE Letter: The 510(k) Pathway for Allograft-based Bone Void Fillers (Group)

Description: This webinar will address the regulatory and scientific considerations for allograft-based bone void filler regulated as devices under FDA's 510(k) pathway in the Center for Devices and Radiological Health (CDRH). Participants will be guided through the 510(k) pathway from product concept to marketing authorization and beyond, including when allograft-based bone void fillers would be considered a device under 510(k), what marketing claims are permissible for these devices, how to identify a predicate, and what types of testing are necessary. The webinar will also include how participants can obtain feedback related to their allograft-based bone void filler and best practices for interacting with FDA.

Educational Objectives:

  • Identify when a 510(k) is needed for allograft-based bone void fillers.
  • Understand how to select a predicate and the substantial equivalence decision-making.
  • Describe the types of non-clinical and animal performance testing necessary to support a 510(k).
  • Understand best practices when interacting with the Agency.


Target Audience: This webinar is designed for tissue bank professionals with expertise in QA/QC, regulatory, research, processing and distribution. 



Laura Rose, PhD

Engagement Partner

Bruder Consulting & Venture Group

Dr. Rose has nearly 8 years of FDA experience and served as the Assistant Director for the Division of Restorative, Repair and Trauma Devices in CDRH’s Office of Orthopedic Devices where she led a large and diverse team of engineers, clinicians, and scientists. She brings a comprehensive understanding of FDA regulations, guidance, and decision-making, as well as a wealth of knowledge about regulation of devices and combination products for tissue engineering and regenerative medicine. She signed multiple Substantial Equivalence (SE) letters for Restorative & Repair orthopedic devices and combination products, including bone void fillers and allograft-based products. Dr. Rose is an Engagement Partner with Bruder Consulting Venture Group (BCVG)

Key:

Complete
Failed
Available
Locked
2024 Webinar Series: From Concept to SE Letter: The 510(k) Pathway for Allograft-based Bone Void Fillers
Select the "View On-Demand Recording" button to begin.  |  60 minutes
Select the "View On-Demand Recording" button to begin.  |  60 minutes
2024 Presentation Survey
6 Questions
Certificate of Attendance
1.00 credit  |  Certificate available
1.00 credit  |  Certificate available